Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Hodgkin Lymphoma
share announcement

Advances in Hodgkin Lymphoma

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (30 September 2020)

Special Issue Editor

Dr. Antonio Gutierrez

E-Mail Website
Guest Editor
Unit of Lymphoma, Service of Hematology, Son Espases University Hospital, Palma, Spain
Interests: lymphoma; lymphoproliferative disorders; chronic lymphoid leukemia; stem-cell transplantation; chimeric antigen T cells; targeted therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hodgkin lymphoma (HL) is a hematologic malignancy with good prognosis as more than 70% of the patients can be cured with current chemotherapy, with or without radiotherapy. However, one-third of the cases finally relapses and needs salvage regimens that are usually consolidated with autologous stem cell transplantation (ASCT). Patients chemoresistant and/or relapsing after ASCT are a great challenge as standard strategies are quite disappointing in this setting. However, we are entering an exciting new era where new drugs or approaches may change the dismal prognosis of relapsing/refractory cases. Antibody-based conjugated therapies such as Brentuximab Vedotin directed against CD30 or ADCT-301 (camidanlumab tesirine) against CD25, or bi-specific antibodies, such as AFM13 that link CD16a and CD30 cells, have improved the specificity of salvage therapy in HL. Immune checkpoint inhibitors may overcome the immune tolerance to this malignancy and promising emergent adaptive immunotherapies based on chimeric antigen T cells (CAR-Ts) may arrive where chemotherapy fails. At the same time, as knowledge about molecular signaling pathways of HL grows, new targeted therapies become tested and eventually will obtain a place in the treatment of HL patients. The challenge will be to define an optimal algorithm for all specific situations using precision medicine.

Dr. Antonio Gutierrez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hodgkin lymphoma
  • new drugs
  • brentuximab
  • camidanlumab tesirine
  • check-point inhibitors
  • chimeric antigen T cells
  • targeted therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 425 KiB  
Article
Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors
by Berbel Ykema, Lisanne Rigter, Manon Spaander, Leon Moons, Tanya Bisseling, Berthe Aleman, Jan Paul de Boer, Pieternella Lugtenburg, Cecile Janus, Eefke Petersen, Judith Roesink, John Raemaekers, Richard van der Maazen, Iris Lansdorp-Vogelaar, Andrea Gini, Wieke Verbeek, Margriet Lemmens, Gerrit Meijer, Flora van Leeuwen, Petur Snaebjornsson, Beatriz Carvalho and Monique van Leerdamadd Show full author list remove Hide full author list
J. Clin. Med. 2020, 9(1), 190; https://doi.org/10.3390/jcm9010190 - 10 Jan 2020
Cited by 5 | Viewed by 3600
Abstract
Background: Hodgkin lymphoma (HL) survivors have an increased colorectal cancer (CRC) risk. Diagnostic accuracy of quantitative fecal immunochemical testing (FIT, OC Sensor) and/or a multi-target stool DNA test (mt-sDNA, Cologuard®) for advanced neoplasia (AN) was evaluated. Methods: 101 HL survivors underwent [...] Read more.
Background: Hodgkin lymphoma (HL) survivors have an increased colorectal cancer (CRC) risk. Diagnostic accuracy of quantitative fecal immunochemical testing (FIT, OC Sensor) and/or a multi-target stool DNA test (mt-sDNA, Cologuard®) for advanced neoplasia (AN) was evaluated. Methods: 101 HL survivors underwent a surveillance colonoscopy and were asked to perform two stool tests (FIT and mt-sDNA). Advanced adenoma (AA), advanced serrated lesion (ASL), and AN (AA, ASL, CRC) were evaluated. Sensitivity, specificity, and area under the curve (AUC) for AN were calculated for different FIT cut-offs and mt-sDNA with colonoscopy as reference. Results: FIT and mt-sDNA were analyzed in 73 (72%) and 82 (81%) participants, respectively. AN was detected in 19 (26%) and 22 (27%), respectively. AN sensitivities for FIT cut-off of 10 ug Hb/g feces (FIT10) and mt-sDNA were 37% (95% confidence interval (CI): 16–62) and 68% (95% CI: 45–86), with corresponding specificities of 91% (95% CI: 80–97) and 70% (95% CI: 57–86), respectively. AUC for FIT was 0.68 (95% CI: 0.54–0.82) and for mt-sDNA 0.76 (95% CI: 0.63–0.89). Conclusions: In HL survivors, mt-sDNA showed highest sensitivity but with relatively low specificity for AN. Cost-effectiveness analyses is necessary to determine the optimal surveillance strategy. Full article
(This article belongs to the Special Issue Advances in Hodgkin Lymphoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

10 pages, 254 KiB  
Review
Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
by Eva Domingo-Domènech and Anna Sureda
J. Clin. Med. 2020, 9(5), 1384; https://doi.org/10.3390/jcm9051384 - 8 May 2020
Cited by 8 | Viewed by 2905
Abstract
Although autologous stem cell transplantation (auto-HCT) is the standard of care for patients with refractory/relapsed (R/R) classical Hodgkin’s lymphoma (cHL), there is still a significant proportion of patients that relapse after the procedure. This review contemplates different treatment strategies for patients with cHL [...] Read more.
Although autologous stem cell transplantation (auto-HCT) is the standard of care for patients with refractory/relapsed (R/R) classical Hodgkin’s lymphoma (cHL), there is still a significant proportion of patients that relapse after the procedure. This review contemplates different treatment strategies for patients with cHL that relapse or progress after auto-HCT. Allogeneic stem cell transplantation (allo-HCT) has, for many years, been the only curative option for this group of patients. Although the advent of haploidentical donors has allowed for the possibility to allograft almost all patients that are in need of it and to eventually improve historical results, allo-HCT is still associated with substantial morbidity and mortality. Brentuximab vedotin (BV) is an antibody drug conjugate that binds to CD30 antigen; BV is able to give up to 34% metabolic complete remissions (mCR) in HL patients that fail auto-HCT. Unleashing the immune system with PD-1 inhibitors has resulted in remarkable responses in a number of malignancies, including HL. Nivolumab and pembrolizumab offer a 20%–25% mCR and 40%–50% partial remissions, with an acceptable safety profile. R/R cHL do have several options nowadays that, without any doubt, have significantly improved the long-term outcome of this hard-to-treat population. Full article
(This article belongs to the Special Issue Advances in Hodgkin Lymphoma)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop